https://scholars.lib.ntu.edu.tw/handle/123456789/612059| Title: | Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan | Authors: | SZU-MIN HSIEH Liu, Ming-Che Chen, Yen-Hsu Lee, Wen-Sen Hwang, Shinn-Jang Cheng, Shu-Hsing Ko, Wen-Chien Hwang, Kao-Pin Wang, Ning-Chi Lee, Yu-Lin Lin, Yi-Ling Shih, Shin-Ru Huang, Chung-Guei Liao, Chun-Che Liang, Jian-Jong Chang, Chih-Shin Chen, Charles Lien, Chia En Tai, I-Chen Lin, Tzou-Yien |
Issue Date: | 2021 | Publisher: | ELSEVIER SCI LTD | Journal Volume: | 9 | Journal Issue: | 12 | Start page/Pages: | 1396 | Source: | The Lancet. Respiratory medicine | Abstract: | MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20-49 years in a phase 1 trial, and provided a good cellular and humoral immune responses. We present the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/612059 | ISSN: | 2213-2600 | DOI: | 10.1016/S2213-2600(21)00402-1 | metadata.dc.subject.other: | [SDGs]SDG3 |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.